Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy. The research indicates comparable response rates in Daratumumab-naïve (DN) and Daratumumab-refractory (DR) patients, with a notable difference in median overall survival (OS). The study explores potential reasons for the higher OS in the DN group and discusses the impact of these findings on treatment decisions for highly refractory multiple myeloma patients. The research also notes similar treatment-related toxicities between DN and DR groups but observes a higher rate of rehospitalization in the daratumumab-refractory group, prompting a discussion on contributing factors and their implications for management and supportive care strategies.
In the context of evolving treatment options for relapsed/refractory multiple myeloma, the study positions VDPACE as a salvage therapy, considering its safety and efficacy profile observed in a real-world analysis. The findings contribute valuable insights to the broader discussion on the sequencing of therapies in this patient population.